Voyageur Minerals’ Joint Venture Company, ImagingX Pharmaceuticals, Submits Third Barium Contrast Product to Health Canada ...
05 Novembro 2019 - 7:00PM
Voyageur Minerals Ltd. (TSX.V:VM) (the
“
Company” or “
Voyageur”) is
pleased to announce the formulation and registration submission to
Health Canada for its new drug
product,
MultiXBa. ImagingX Pharmaceuticals
Ltd (“ImagingX”), a Voyageur joint-venture company described below,
has submitted a total of three products for registration to Health
Canada, with two more products anticipated to follow in the near
term.
MultiXBa is a specially formulated low density
dry Barium powder. It is engineered to be mixed with water to
create a Barium Sulfate suspension for oral consumption to aid in
radiographic X-ray procedures to view the upper gastrointestinal
tract (esophagus, stomach, duodenum). MultiXBa is similar in
composition to HDXBa; however, the barite has been selectively
ground to 1 - micron size. MultiXBa will provide ultra-fine
particle distribution for superior coating of the GI Trac.
ImagingX is continuing to develop multiple
products and is currently developing its Iodine contrast. ImagingX
intends to submit two additional Barium products to Health Canada
in the near term:
MultiXthick -
High Density Liquid Barium
MultiXthin -
Low Density Liquid Barium
About Voyageur
Voyageur Minerals Ltd. is a Canadian public
company listed on the TSX Venture Exchange under the trading symbol
VM. Voyageur is focused on the development of Active Pharmaceutical
Ingredients (API) minerals. The current focus is developing barite
and Iodine radiocontrast products and developing Bromine based
pharmaceutical products.
Voyageur’s goal is to generate positive cash
flow from operations through its recently signed joint venture with
Chief Medical Supply Ltd. – Alberta’s only pharmaceutical
manufacturer. The joint venture contemplates turnkey manufacturing,
bottling and distribution of Barium radiopharmaceuticals for MRI,
X-ray and CT scan applications. The Company also contemplates a
similar Health Canada registration application for Iodine and
Bromine products also for medical applications.
Voyageur owns 100% interest in three barium
sulfate ("Barite") deposits including two properties suitable in
grade for the industrial barite market place, including interests
in a high-grade iodine, lithium & bromine brine project in
Utah, USA.
About ImagingX
Pharmaceuticals
Voyageur formed ImagingX, a gross revenue
sharing joint venture company with Chief Medical Supply Ltd (CMS).
CMS provides high quality, competitively priced pharmaceuticals and
hemodialysis products to pharmacies and hospitals across Canada.
Operating from both its 81,000 square-foot plant in Calgary,
Alberta and its 163,000 square-foot facility in Mississauga,
Ontario, CMS can supply products coast-to-coast. Regulated by
Health Canada and complying with the Canadian Food and Drug Act,
CMS has both drug and medical device establishment licenses issued
by Health Canada. CMS currently has the combined bottling capacity
of 760,000 bottles per day and has a turnkey sterile bottle line
ready for ImagingX iodine contrast production.
ImagingX plans to employ a strategy of selling
competitively priced radiopharmaceuticals for MRI, X-ray and CT
scan applications. The main focus is on Barium and Iodine based
products. The joint venture obligates Voyageur to provide the
Active Pharmaceutical Ingredient minerals for the products and CMS
to manufacture the products. The partners split gross revenue
50/50. This joint venture relationship is designed for ImagingX to
be highly competitive by controlling all input costs under the
motto of:
“From the Earth to the
Bottle”
For further information, please contact:
Steven R. LivingstonCell: (403) 471-1659Office:
(587)-779-6166steve@voyageurminerals.cawww.voyageurminerals.ca
Reader Advisory
Neither the TSXV nor its Regulation Services
Provider (as that term is defined in the policies of the TSXV)
accepts responsibility for the adequacy or accuracy of this news
release.
Cautionary Note Regarding
Forward-Looking Statements:
This news release contains certain statements or
disclosures relating to the Company that are based on the
expectations of its management as well as assumptions made by and
information currently available to the Company which may constitute
forward-looking statements or information ("forward-looking
statements") under applicable securities laws. All such statements
and disclosures, other than those of historical fact, which address
activities, events, outcomes, results or developments that the
Company anticipates or expects may, or will occur in the future (in
whole or in part) should be considered forward-looking statements.
In some cases, forward-looking statements can be identified by the
use of the words "will", "intend," “anticipates”, “plans” and
similar expressions.
In particular, but without limiting the
foregoing, this news release contains forward-looking statements
pertaining to anticipated registrations with Health Canada for
various pharmaceutical products the Company’s plan to develop,
produce and sell certain products, and anticipated cash
flows. Although Voyageur believes that expectations and
assumptions on which the forward-looking statements and information
are based are reasonable, undue reliance should not be placed on
the forward-looking information and statements because Voyageur
cannot give any assurances that they will prove to be correct.
Forward looking statements are based on the opinions and estimates
of management of management at the date hereof and are subject to a
variety of risks and uncertainties and other factors that could
cause actual events or results to differ materially from those
projected in the forward-looking statements, including but not
limited to expectations and assumptions concerning the
registrations of ImagingX’s products with Health Canada and the
ability to obtain the benefits thereof, the ability of the Company
to produce barite from its mineral properties for the key
ingredient for ImagingX’s Barium products and delays or changes in
plans with the joint venture partner. The Company cannot assure
that actual results will be consistent with these forward-looking
statements.
The forward-looking statements contained in this
news release are made as of the date hereof and the Company
undertakes no obligations to update publicly or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, unless so required by applicable
securities laws.
Voyageur Pharmaceuticals (TSXV:VM)
Gráfico Histórico do Ativo
De Nov 2024 até Dez 2024
Voyageur Pharmaceuticals (TSXV:VM)
Gráfico Histórico do Ativo
De Dez 2023 até Dez 2024